Sensyne Health plc, the clinical AI company, has signed a five year non-exclusive Strategic Research Agreement (SRA) with the Royal Devon and Exeter NHS Foundation Trust. The agreement will enable the ethical application of clinical AI research to improve patient care and accelerate research into new medicines.
The Royal Devon and Exeter NHS Foundation Trust dataset covers 1.2 million unique patient records, with 110,000 annual hospital admissions (2019/20) from a patient population of approximately 450,000 people.
The new agreement combined with NHS England approval of SRAs with George Eliot Hospital NHS Trust and Wye Valley NHS Trust brings combined total of anonymised data available to Sensyne to 8.5 million patients. Sensyne Health is a clinical artificial intelligence company operating a unique business model. It is a for-profit plc sharing its financial returns with health trusts via equity and a share of revenues.
All data supplied to Sensyne will be anonymised by RD&E beforehand and the provision of the data will operate under an agreed Data Processing Protocol under RD&E ethical oversight.
The Trust will receive 1,428,571 ordinary shares in Sensyne Health plc representing 0.87 per cent of the existing issued share capital of Sensyne. This brings the total share ownership held by NHS Trusts in Sensyne to 13.3 per cent (as enlarged by the expected issue of shares to RD&E, George Eliot Hospital NHS Trust and Wye Valley NHS Trust).
The Royal Devon and Exeter NHS Foundation Trust will also receive from Sensyne an investment of up to £250,000 per year over the 5-year term of the contract for specific investments in information technology to enable the ethical curation and analysis of anonymised data under the SRA. The Trust will receive a royalty on revenues that are generated by Sensyne from the research undertaken under the SRA. The financial return RD&E receives from Sensyne will be reinvested back into the NHS to enhance patient care. The Trust has entered into a lock-up agreement whereby it has agreed not to dispose of any shares for a period of two years from the date the shares are issued.
Separately, Sensyne confirms that the SRAs with George Eliot Hospital NHS Trust and Wye Valley NHS Trust, announced on 28 January 2019, have now received NHS England approval. Together with the new RD&E agreement this brings the combined total of anonymised data available for analysis by Sensyne up from 6.8 million to 8.5 million patients.
The Royal Devon and Exeter NHS Foundation Trustjoins existing SRAs the Company has in place with Oxford University Hospitals NHS Foundation Trust, Chelsea & Westminster Hospitals NHS Foundation Trust, South Warwickshire NHS Foundation Trust, Wye Valley NHS Trust, George Eliot Hospital NHS Trust, Milton Keynes University Hospital NHS Foundation Trust, Somerset NHS Foundation Trust, Hampshire Hospitals NHS Foundation Trust and Royal Wolverhampton NHS Trust and a data access agreement signed with NHS Greater Glasgow and Clyde.